Overall survival benefit from tebentafusp in patients with best response of progressive disease. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results